Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 02, 2015 11:05 AM ET

Biotechnology

Company Overview of Affimed N.V.

Company Overview

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, a natural killer cell bispecific antibody (TandAb) that completed Phase I clinical trial for the treatment of various CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The company’s product candidates also include AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor v...

Technologiepark

Im Neuenheimer Feld 582

Heidelberg,  69120

Germany

Founded in 2000

52 Employees

Phone:

49 6221 65307 0

Fax:

49 6221 65307 77

Key Executives for Affimed N.V.

Chief Executive Officer and Member of Management Board
Age: 53
Total Annual Compensation: $297.0K
Chief Financial Officer and Member of Management Board
Age: 47
Total Annual Compensation: $190.0K
Chief Medical Officer and Member of Management Board
Age: 52
Total Annual Compensation: $352.0K
Compensation as of Fiscal Year 2014.

Affimed N.V. Key Developments

Affimed N.V. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Affimed N.V. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company’s revenue was €2,210,000 against €687,000 last year. Operating loss was €4,967,000 against operating income of €7,198,000 last year. Loss before taxes was €5,184,000 against income before tax of €13,395,000 last year. Net loss was €5,184,000 or €0.19 per undiluted and diluted share against net income of €13,354,000 or €0.90 per undiluted and diluted share last year. The decrease is primarily related to the fact that prior to the corporate reorganization at the time of the IPO in September 2014, share-based payments were accounted for as liabilities with fair value adjustments each quarter. The revenue in the second quarter of 2015 was mainly attributable to revenue recognition upon achievement of milestones pursuant to the Leukemia & Lymphoma Society (LLS) collaboration and provision of research and development services provided to Amphivena. For the six months, the company’s revenue was €4,748,000 against €1,409,000 last year. Operating loss was €6,969,000 against €2,116,000 last year. Loss before taxes was €6,668,000 against €2,320,000 last year. Net loss was €6,668,000 or €0.26 per undiluted and diluted share against €2,292,000 or €0.15 per undiluted and diluted share last year. Net cash flow used in operating activities was €7,848,000 against €3,497,000 a year ago. Purchase of intangible assets was €6,000 against €23,000 a year ago. Purchase of leasehold improvements and equipment were €82,000 against €19,000 a year ago. The increase was mainly due to higher research and development (R&D) and general and administrative-related (G&A) expenses compared to the same period last year.

Affimed N.V. to Report Q2, 2015 Results on Aug 04, 2015

Affimed N.V. announced that they will report Q2, 2015 results on Aug 04, 2015

Affimed N.V., Q2 2015 Earnings Call, Aug 04, 2015

Affimed N.V., Q2 2015 Earnings Call, Aug 04, 2015

Similar Private Companies By Industry

Company Name Region
Protagen Protein Services GmbH Europe
Source BioScience imaGenes Europe
QIAGEN GmbH Europe
t-cell Europe GmbH Europe
Genethor GmbH Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Affimed N.V., please visit www.affimed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.